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1. Introduction 
The goals for this chapter are to succinctly describe the definition of anemia, and to describe 
the pathophysiology and the epidemiology of anemia in diabetic patients with chronic 
kidney disease. In addition, the cardiovascular risk factors of anemic patients will be 
explained and a table will be included. A comprehensive visualization will be included 
which will incorporate the pathophysiology of anemia in chronic kidney disease and the 
negative impact of anemia on the cardiovascular system. Reasons to treat anemia in this 
population will be presented. Furthermore, the recent clinical trials on anemia treatment in 
the diabetic patient with chronic kidney disease will be discussed, including but not limited 
to the CHOIR, CREATE, ACORD and TREAT trials. Lastly, there will be a summary of the 
most important points of the chapter. CHOIR (Correction of Hemoglobin and Outcomes in 
Renal Insufficiency), CREATE (Cardiovascular Risk Reduction by Early Anemia Treatment 
with Epoetin Beta), ACORD (Anemia Correction in Diabetes) and TREAT (Trial to Reduce 
Cardiovascular Events with Aranesp Therapy) trials. 
With the ongoing pandemic of obesity, diabetes and hypertension, chronic kidney disease is 
becoming a leading global health problem. Diabetes is currently the most common cause of 
chronic kidney disease [1]. Patients with diabetes and chronic kidney disease have an 
increased risk for anemia.  Anemia is a risk factor for cardiac dysfunction and is potentially 
modifiable. Therefore it should be screened for readily in the diabetic population, a 
particularly vulnerable population, and it should be identified and rectified promptly. 
However all too often this is not the case.  
2. Definition of anemia 
According to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
(NKF KDOQI), anemia is defined as hemoglobin levels of less than 13.5g/dL (135 g/L) for 
men and less than 12.0g/dL (120 g/L) for women [2]. The WHO criteria defines anemia to be 
less than 13.0g/dL (130 g/L) for men and less than 12.0g/dL for premenopausal women [3].  
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3. Risk factors for anemia 
Patients with diabetes and CKD had the highest risk of anemia (odds ratio 1.73, 95% CI 1.63-
1.83) [6,7]. Other risk factors that significantly increase the odds of anemia included lower 
educational level, diabetes mellitus, hypertension, cardiovascular disease (CVD), and 
chronic kidney disease (CKD), with risk greatest for patients with diabetes and CKD [6]. 
 
Risk Factors For Anemia  
in CKD patients: 
1. Diabetes 
2. Chronic Kidney Disease 
3. Cardiovascular Disease 
4. Hypertension 
5. Low Education Levels 
6. African American race 
4. Ethnicity 
African Americans have significantly greater incidences of anemia, with mean hemoglobin 
being 13.5g/dL for African American vs. 15.3g/dL for white men and 12.5g/dL vs. 
14.7g/dL for: African American and White Women respectively [4]. This difference can be 
due in part to the fact that approximately 30 percent of African Americans carry a 3.7kb 
deletion in the alpha thalassemia gene. Homozygotes for alpha thalassemia exhibit a mild, 
microcytic anemia, while even heterozygotes may have a low-normal or mildly decreased 
hemoglobin. However even when people with alpha thalassemia gene, iron deficiency, renal 
insufficiency and sickle cell trait are excluded, the difference between the hemoglobin of 
African Americans and whites still persists, albeit to a lower degree [5]. The cause of this 
phenomenon still remains to be discovered. In the meantime, it has been debated whether 
the definition of anemia should be modified for different racial and ethnic groups, although 
this has not yet been implemented in clinical practice guidelines. 
5. Pathophysiology of anemia in diabetics with chronic kidney disease 
There are several factors which have been implicated in the development of anemia in 
CKD which include erythropoietin deficiency, iron deficiency, decreased lifespan of red 
blood cells, chronic blood loss, secondary hyperparathyroidism, chronic inflammation, 
oxidative stress, nutritional folate deficiency, uremia and chronic suppression of 
erythropoesis [6,7]. 
Diabetes exacerbates many of these factors, leading to a higher degree of anemia in patients 
with diabetic nephropathy than in patients with kidney disease from other causes.  
6. Erythropoietin deficiency 
Erythropoietin (EPO) is a glycoprotein hormone that regulates proliferation, differentiation 
and maturation of red blood cells. EPO is produced by the peritubular capillary cells within 
the kidney, and this process is mediated by oxygen availability. In normal kidneys, EPO 
production increases in proportion to the degree of anemia.  
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Relative deficiency of EPO is the most important cause of anemia in patients with chronic 
kidney disease. The ability of the kidneys to produce erythropoietin is not impaired in renal 
disease - the absolute value of EPO can be in the normal or even high, so measuring EPO 
levels does not aid clinical management. However EPO levels will be inappropriately low 
relative to the degree of anemia, resulting in a functional EPO deficiency. This is due to the 
uncoupling of EPO synthesis from hemoglobin concentration so that the protein is no longer 




In the diabetic kidney tubulointerstitial dysfunction is observed early in the course of 
disease [9]. This could cause disruption of the intricate signaling mechanism between the 
capillaries, interstitial fibroblasts and tubular cells regulating EPO production, thus 
contributing to the uncoupling of EPO synthesis from hemoglobin levels. 
Diabetes also negatively affects hypoxia-inducible factor (HIF), a transcription factor that 
plays a crucial role in regulating the renal response to hypoxia. HIF regulates the 
transcriptional activation of many oxygen-sensitive genes, including EPO. Hyperglycemia 
has been shown to inhibit stabilization of the HIF protein [10]. 
Autonomic dysfunction has also been suggested as another factor that may contribute to 
EPO deficiency in diabetic patients. In experimental models, EPO production is impaired 
when the kidney is denervated [11]. Also, patients with primary disorders of the autonomic 
nervous system have blunted production of EPO and a high risk of developing anemia [12].  
7. Decreased red blood cell lifespan 
Patients with renal disease have a 30 to 70 percent reduction in RBC lifespan. The 
mechanism of this phenomenon has yet to be elucidated satisfactorily. Blood from uremic 
donors transfused into normal recipients result in normal RBC survival, implying that the 
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uremic environment of patients with chronic kidney disease is the underlying cause of this 
phenomenon. However advancements in chronic renal replacement therapy does not lead to 
improvement in RBC survival [13]. 
The red blood cells of patients with diabetes are metabolically and functionally abnormal. 
These changes contribute to reduced erythrocyte survival in diabetic patients to a greater 
degree than in nondiabetic patients with a similar degree of renal impairment [14].  
8. Iron deficiency 
Uremia causes platelet dysfunction, putting patients with chronic kidney disease at 
increased risk of bleeding and iron loss. Patients on hemodialysis in particular are prone to 
losing iron through blood trapping in dialysis machine and repeated phlebotomy.  
It has also been shown that patients with chronic kidney disease have impaired absorption 
of dietary iron. Transferrin is a protein that delivers iron from the gastrointestinal tract and 
the reticuloendothelial system into the bone marrow to be utilized by maturing 
erythrocytes. Patients with chronic kidney disease have decreased levels of transferrin, 
impairing iron mobilization [15]. 
The overall prevalence of iron deficiency in patients with diabetes is not significantly 
different from that in the general adult population. However, normal iron indices do not 
preclude these patients from achieving benefit with iron supplementation. In particular, 
patients on dialysis are often found to have a functional iron deficiency, in which their iron 
studies are normal but their anemia improves with parenteral iron supplementation. 
9. Chronic inflammation and oxidative stress 
Anemia of chronic inflammation is characterized by an impairment of the ability to release 
iron from the hepatocytes and macrophages of the reticuloendothelial system. Patients with 
chronic kidney disease exhibit a generalized increase in the inflammatory response due to a 
variety of factors, including decreased clearance of imflammatory cytokines, volume 
overload, oxidative stress and their underlying comorbid conditions.  
Although decreased GFR and decreased iron stores are major contributing factors to anemia 
in diabetic patients, EPO deficiency and inflammation are becoming a leading factors in 
explaining the high prevalence of anemia in diabetics with CKD. These factors lead to 
anemia and lead to heart failure, cardiomyopathy and myocyte death [16]. 
10. Epidemiology of anemia in diabetic populations with chronic kidney 
disease 
Anemia occurs earlier, and is more severe in chronic kidney disease related to diabetes than in 
non-diabetic kidney disease. It often develops when creatinine is within the normal range, and 
therefore is undiagnosed by primary care physicians.  Anemia has a negative impact on 
patient’s quality of life contributing to morbidity, for instance worsening exercise tolerance, 
lethargy and erectile dysfunction [17]. Furthermore anemia causes hypoxia induced diseases, 
including angina, cardiac failure and claudication, which are also independently associated 
with diabetes. Studies have shown that approximately 20 to 30 percent of people with diabetes 
will be anemic [18]. Unfortunately anemia within the diabetic population anemia is often 
unrecognized, undetected and untreated in patients with chronic kidney disease [19].  
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Anemia in diabetic patients although prevalent is often overlooked and undertreated. A 
cross sectional study comprised of a questionnaire-based interview with 1054 respondents 
form 6 European countries (Belgium, France, Germany, Greece Italy and the UK) showed 
that only 32 percent of respondents had been given information about anemia, although 83 
percent had heard of anemia.  One fifth of those with anemia received no treatment. 
Although anemia is highly prevalent in those with diabetes, patients are often unaware and 
undertreated for their anemia [20]. 
11. Cardiovascular risks of anemic patients with chronic kidney disease 
Cardiovascular disease is very common in patients with diabetes and with CKD. There are 
numerous important interactions between heart disease and renal disease, a term defined as 
cardiorenal syndrome (CRS).  A 2004 report from the National Heart, Lung, and Blood 
Institute defined CRS as a condition in which therapy to relieve congestive symptoms of 
heart failure is limited by a decline in renal function as manifested by a reduction in 
glomerular filtration rate.  For instance acute heart failure results in acute kidney injury and 
chronic heart failure causes progressive chronic kidney disease [21]. This association leads to 
the vicious circle contributing to premature death [22]. 
As randomized, placebo-controlled trials have so far been disappointing and unable to show 
a survival benefit of various treatment strategies, such as lipid-lowering, the risk factor 
profile seems to be different in CKD compared with the general population.  Indeed, 
seemingly paradoxical associations between traditional risk factors and cardiovascular 
outcome in patients with advanced CKD have complicated our efforts to identify the real 
cardiovascular culprits. There are several non-traditional cardiovascular risk factors that are 
directly linked with CKD such as hyperparathyroidism, hyperphosphatemia, 
hyperhomocysteinemia and anemia, which are increasingly, recognized as cardiovascular 
risks [23]. Patients with CKD are more likely to die from cardiovascular events than of end 
stage renal disease.  
12. Cardiovascular risk factors 
In a study done involving 69,244 participants in a voluntary screening program and 17,061 
participants randomly selected national survey population, CKD was independently 
associated with MI or stroke [6]. In diabetic patients with CKD the risk of CVD is increased 
by 20 to 40 percent compared with that in CKD in patients without diabetes [24].  
 
 
Traditional Risk Factors  
 
Non traditional risk Factors 
Diabetes Chronic inflammation 
Dyslipidemia Anemia 
HTN Oxidative stress 
Central obesity Hyperparathyroidism 
Smoking Hyperhomocysteinemia 
Male or postmenopausal female Endothelial Dysfunction 
Family history of MI event Prothrombotic states 
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13. Reasons to treat anemia  
Type 2 diabetes mellitus and chronic kidney disease frequently coexist, and each disease 
independently increases the risk of cardiovascular events and end stage renal disease. 
Intensive treatment of risk factors such as hypertension and elevated LDL reduces 
cardiovascular morbidity and mortality and slows the progression of the kidney disease [25-
27]. Anemia is a risk factor for cardiovascular morbidity and mortality, and is evolving as an 
attractive target and potentially correctable risk factor [24]. 
14. Treatment recommendations 
All patients with CKD should be screened at least annually for anemia, regardless of stage. 
Further evaluation of anemia should be initiated in patients with CKD if hemoglobin levels 
found to be below normal, including iron studies. Erythropoiesis-stimulating agents (ESAs) 
can be initiated when hemoglobin falls below the target range of 11-12g/dL [16]. 
ESAs are the mainstay of therapy for anemia of chronic kidney disease. There are currently 
two agents commercially available, recombinant epoietin alfa (Epogen, Procrit) and 
darbepoetin alfa (Aranesp). The selection of ESA can be individualized according to clinical 
circumstances and patient/provider preference.  
Patients with serum ferritin, transferrin saturation and/or content of hemoglobin in 
reticulocytes below target levels should be started on iron supplementation. Patients on 
hemodialysis should be given parenteral iron therapy as their iron deficiency often fails to 
correct with oral supplementation. 
15. Recent clinical trials 
Recommendations regarding the use of erythropoietin and the target hemoglobin are 
forever changing. In 1994 The FDA first approved a target hemoglobin of 10-11g/dl which 
was subsequently increased to 10-12g/dl in 1998. The National Kidney Foundation 
recommended a level of hemoglobin of 11-12g/dl in 2007 [2,6]. 
In 1998 a study was performed to assess the risks and benefits of normalizing the hematocrit 
in patients with cardiac disease who were undergoing hemodialysis. There were 1233 
patients evaluated in the study, of which 618 were assigned to achieve a hematocrit of 42 
percent, and 615 received erythropoietin sufficient to achieve and maintain a hematocrit of 
30 percent.  After 29 months there were 183 deaths and 19 first nonfatal myocardial infarcts 
among the patients in the normal hematocrit group and 150 deaths and 14 non-fatal 
myocardial infarcts among those in the low hematocrit group. The study was prematurely 
halted due to the higher mortality rate in the normal hematocrit group. The investigators 
recommended against normalization of hematocrit in patients with clinically evident 
congestive heart failure or ischemic heart disease who are receiving hemodialysis [28]. 
In 2006 two other landmark trials were published. The studies were conducted to determine 
optimal hemoglobin levels in predialysis patients looking at cardiovascular disease 
outcomes. 
The CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) study was an 
open-label trial of 1432 patients with CKD. 715 were randomly assigned to receive epoetin 
alpha to achieve a hemoglobin of 13.5g/dl and 717 were assigned to achieve a level of 
11.3g/dl. The endpoint was a composite of death, myocardial infarction, hospitalization for 
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congestive heart failure, and stroke. There were 222 composite events: 125 in the high 
hemoglobin group and 97 in the low hemoglobin group. Investigators concluded that the 
13.5g/dl target resulted in increased risk, and no improvement in quality of life [29]. 
The second landmark trial at this time was the CREATE (Cardiovascular Risk Reduction by 
Early Anemia Treatment with Epoetin Beta) study, which randomly assigned 603 patients 
with an estimated GFR of 15-35 ml/min and mild to moderate anemia (11-12.5 g/dl) to a 
target hemoglobin in the normal range (13-15g/dl) or to subnormal values (10.5-11.5g/dl). 
During the 3 year study complete correction of anemia did not affect the likelihood of a first 
cardiac death. There was no significant incidence of adverse events between the two groups. 
Investigators concluded that in patients with CKD, early complete correction of anemia does 
not reduce the risk of cardiovascular events [30]. 
The ACORD (Anemia Correction in Diabetes) study, published in 2007, investigated the 
effect of correcting anemia on heart function in diabetic patients with anemia and early 
diabetic nephropathy. 172 patients with type 1 or 2 diabetes mellitus, mild to moderate 
anemia, and stage 1 to 3 chronic kidney disease were randomly assigned to attain a target 
hemoglobin level of either 13 to 15 g/dL (group 1) or 10.5 to 11.5 g/dL (group 2). The 
primary end point was change in left ventricular mass index (LVMI), measured by 
echocardiogram. At study end, hemoglobin levels were 13.5 g/dL in group 1 and 12.1 g/dL 
in group 2, but no significant differences between study groups were observed in median 
LVMI after 15 months [31].  
In 2009 the TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy) trial was 
conducted to evaluate whether increasing the hemoglobin level with the use of darbepoetin 
would lower the rate of death, cardiovascular events or end stage renal disease in patients 
with type 2 diabetes and chronic kidney disease. This was a randomized, double blind 
placebo controlled trial conducted at 623 sites in 24 countries consisting of 4038 patients. 
2012 patients were randomly assigned to receive darbepoetin to achieve a hemoglobin level 
of approximately 13g/dL, while 2026 patients received placebo, with rescue darbepoetin 
when the hemoglobin level was less that 9g/dL. Darbepoetin did not reduce the primary 
end points of death, cardiovascular events or end stage renal disease in patients with 
diabetes and chronic kidney disease. There was also an increased incident of stroke of 2.1 
percent in the darbepoetin arm vs. 1.1 percent in the placebo arm [32]. 
A subset analysis of TREAT that was published in September 2010 assessed the relationship 
between responsiveness to darbepoetin, hemoglobin levels achieved, and cardiovascular 
outcomes in patients with chronic kidney disease and type 2 diabetes. Patients with less 
than 2 percent change in hemoglobin level after the first two doses of darbepoetin were 
defined as poor responders. These patients had a lower hemoglobin level at 12 weeks 
despite receiving higher doses of darbepoetin. They also had higher rates of composite 
cardiovascular end points or death. The study was unable to determine whether poor 
response to darbepoetin is a risk factor for adverse outcomes, or whether the risk was 
augmented by the higher doses of darbepoetin they received [33].  
16. Conclusion 
Although anemia in chronic kidney disease is often unrecognized and under diagnosed, it is 
an important predictor of quality of life and contributes to cardiovascular morbidity and 
mortality in patients with diabetes. Anemia causes hypoxia induced diseases, including 
angina, cardiac failure and claudication, which are also independently associated with 
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diabetes. Anemia also causes worsening exercise tolerance, lethargy and erectile 
dysfunction. Anemia, like hypertension and hyperlipidemia is an important modifiable risk 
factor in patients with chronic kidney disease and diabetes, therefore should be treated as 
such.  
Currently it is recommended to maintain a hemoglobin of 11-12g/dl in patients with chronic 
kidney disease with correction of nutritional deficiencies and the use of erythropoietin-
stimulating agents. Evidence from randomized controlled trials including the CHOIR, 
CREATE and ACORD studies show that normalization of hemoglobin beyond 12g/dl does 
not improve outcomes. The TREAT trial showed that using ESAs to increase hemoglobin to 
a target of 13g/dL increases the risk of stroke. It was also found that patients who had a 
poor response to ESAs had a higher rate of cardiovascular events. 
17. Summary 
1. Anemia is pervasive in the diabetic patient with CKD. 
2. Anemia occurs earlier, and is more severe in chronic kidney disease related to diabetes 
than in non-diabetic kidney disease. 
3. Reasons for anemia in CKD include EPO deficiency, iron deficiency, decreased lifespan 
of red blood cells, chronic blood loss, secondary hyperparathyroidism, chronic 
inflammation, oxidative stress, nutritional folate deficiency, uremia and chronic 
suppression of erythropoesis.  
4. Anemia in diabetic patients although prevalent is often overlooked and undertreated. 
5. Cardiovascular disease is very common in patients with diabetes and with CKD. 
6. In diabetic patients with CKD the risk of CVD is increased by 20 to 40 percent 
compared with that in CKD in patients without diabetes. 
7. Anemia is a risk factor for cardiovascular morbidity and mortality, and is evolving as 
an attractive target and potentially correctable risk factor. 
8. All patients with CKD should be screened at least annually for anemia, regardless of 
stage. 
9. ESAs are the mainstay of therapy for anemia of chronic kidney disease. 
10. Maintaining a hemoglobin of 11-12g/dl is currently recommended.  
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